Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
| Revision | Operations | |
|---|---|---|
| 06-13-22 by conan.macdougal... | current revision | |
| 07-26-21 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 07-10-20 by [email protected] | ||
| 04-22-20 by ucsf_admin | ||
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | Dose | Notes |
|---|---|---|
| Clostridioides difficile infection: initial episode, non-fulminant | 125 mg PO QID | No renal dose adjustment |
| Clostridioides difficile infection: fulminant | 500 mg PO QID* |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
| Indication | Dose | Notes |
|---|---|---|
| Clostridioides difficile infection: non-fulminant | 125 mg PO QID | No dose adjustment in hemodialysis |
| Clostridioides difficile infection: fulminant | 500 mg PO QID |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.
*Consider additional rectal instillation
See IDMP guidelines for greater detail and vancomycin taper dosing: https://idmp.ucsf.edu/content/management-clostridium-difficile-infection-adults
PO vancomycin is NOT sufficiently absorbed to treat systemic infections